
NeuroSense Reports Breakthrough in ALS Treatment Study
NeuroSense Therapeutics has successfully reached the primary endpoint in its Phase 2b clinical trial for PrimeC, becoming the first to demonstrate a statistically significant reduction of TDP-43 in patients with amyotrophic lateral sclerosis. The findings offer biological evidence that the drug engages a core driver of the disease.

























